Ticker LaunchLondon · AIM · IPO · VRCI
Verici Dx plc
Verici Dx plc (VRCI) was admitted to AIM on Nov 3, 2020, raising £14.5M at 20p per share. Its market capitalization at admission was about £28.4M. N+1 Singer acted as nominated adviser.
Verici Dx plc is an immuno-diagnostics development company focused on kidney transplantation. It develops sequencing-based tests, including Clarava for pre-transplant risk and Tuteva for post-transplant rejection.
- Type
- IPO
- Market
- AIM
- Ticker (TIDM)
- VRCI
- Admitted
- Nov 3, 2020
- Offer price
- 20p
- Raised
- £14.5M
- Market cap at admission
- £28.4M
- Nominated adviser
- N+1 Singer
- Brokers
- N+1 Singer
- Sector
- Biotech & pharma
- Country
- United Kingdom
More on this listing for subscribers
- Intention-to-float date
- New money versus sale shares
- Shares in issue at admission
- ISIN
- Source announcements
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Sources
From company announcements filed with the FCA's National Storage Mechanism. Subscribers see the list of announcements for each listing.
Other London listings around the same time
- Round Hill Music Royalty Fund LimitedMain Market · Nov 13, 2020
- SourceBio International plcAIM · Oct 29, 2020
- Wheaton Precious Metals Corp.Main Market · Oct 28, 2020
- Anemoi International LtdMain Market · Oct 26, 2020
- SDIC Power Holdings Co., LtdMain Market · Oct 22, 2020
- JSC Kaspi.kzMain Market · Oct 20, 2020